PL1976548T3 - Fragmenty VIP i ich kompozycje - Google Patents

Fragmenty VIP i ich kompozycje

Info

Publication number
PL1976548T3
PL1976548T3 PL06817603T PL06817603T PL1976548T3 PL 1976548 T3 PL1976548 T3 PL 1976548T3 PL 06817603 T PL06817603 T PL 06817603T PL 06817603 T PL06817603 T PL 06817603T PL 1976548 T3 PL1976548 T3 PL 1976548T3
Authority
PL
Poland
Prior art keywords
compositions
vip fragments
vip
fragments
Prior art date
Application number
PL06817603T
Other languages
English (en)
Inventor
Karen Annette Duggan
Original Assignee
Vectus Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38122420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1976548(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2005906947A external-priority patent/AU2005906947A0/en
Application filed by Vectus Biosystems Ltd filed Critical Vectus Biosystems Ltd
Publication of PL1976548T3 publication Critical patent/PL1976548T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL06817603T 2005-12-09 2006-12-08 Fragmenty VIP i ich kompozycje PL1976548T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2005906947A AU2005906947A0 (en) 2005-12-09 VIP fragments and methods of use
PCT/AU2006/001869 WO2007065226A1 (en) 2005-12-09 2006-12-08 Vip fragments and methods of use
EP06817603.1A EP1976548B1 (en) 2005-12-09 2006-12-08 VIP fragments and compositions thereof

Publications (1)

Publication Number Publication Date
PL1976548T3 true PL1976548T3 (pl) 2015-01-30

Family

ID=38122420

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06817603T PL1976548T3 (pl) 2005-12-09 2006-12-08 Fragmenty VIP i ich kompozycje

Country Status (19)

Country Link
US (4) US8470778B2 (pl)
EP (2) EP2783697B1 (pl)
JP (3) JP5449778B2 (pl)
KR (2) KR101404561B1 (pl)
CN (2) CN101325964B (pl)
AR (2) AR058308A1 (pl)
AU (1) AU2006322656B2 (pl)
BR (1) BRPI0620566B8 (pl)
CA (2) CA2952475C (pl)
DK (2) DK1976548T3 (pl)
ES (2) ES2621864T3 (pl)
IL (3) IL192046A (pl)
NZ (4) NZ569401A (pl)
PL (1) PL1976548T3 (pl)
PT (1) PT1976548E (pl)
RU (1) RU2466738C2 (pl)
TW (1) TWI402273B (pl)
WO (1) WO2007065226A1 (pl)
ZA (1) ZA200805837B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1768689B1 (en) * 2004-06-11 2014-08-20 Vectus Biosystems Limited Compositions and methods for treatment of cardiovascular disease
WO2007016271A2 (en) * 2005-07-28 2007-02-08 Global Research Technologies, Llc Removal of carbon dioxide from air
AU2006322656B2 (en) 2005-12-09 2012-03-08 Vectus Biosystems Limited VIP fragments and methods of use
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP1971355B1 (en) 2005-12-20 2020-03-11 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
CN105727261A (zh) 2008-06-27 2016-07-06 杜克大学 包含弹性蛋白样肽的治疗剂
WO2010042997A1 (en) * 2008-10-17 2010-04-22 Vectus Biosystems Pty Limited Compositions and methods for treatment of kidney disorders
CN101434649B (zh) * 2008-12-12 2012-04-25 余榕捷 一种环七肽及其制备方法和应用
BRPI1006748A2 (pt) * 2009-04-02 2018-03-06 Vectus Biosystems Pty Ltd método de tratamento profilático ou terapêutico de fibrose aórtica em um indivíduo, peptídeo intestinal vasoativo (vip), uso do peptídeo intestinal vasoativo (vip), método para reduzir a formação de colágeno ou para realçar a degradação de colágeno na orta de um indivíduo, e, composição para o tratamento profilático ou terapêutico de fibrose aórtica
IN2012DN02120A (pl) 2009-08-14 2015-08-21 Phasebio Pharmaceuticals Inc
ES2669190T3 (es) 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión
MX368865B (es) * 2013-09-17 2019-08-02 Vectus Biosystems Ltd Composiciones para el tratamiento de hipertension y/o fibrosis.
US9375638B2 (en) * 2014-01-02 2016-06-28 Lloyd A. Weaver Game console switch box
EP3139949B1 (en) 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
ES2822598T3 (es) * 2015-02-09 2021-05-04 Phasebio Pharmaceuticals Inc Métodos y composiciones para tratar enfermedades y trastornos musculares
SG11201707561RA (en) * 2015-03-18 2017-10-30 Vectus Biosystems Ltd Compositions for the treatment of fibrosis and fibrosis-related conditions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862927A (en) * 1973-02-26 1975-01-28 Sami I Said Process for preparation of vasoactive intestinal peptide
US4016258A (en) * 1975-08-05 1977-04-05 Said Sami I Vasoactive intestinal peptide from fowl
US4237046A (en) * 1979-04-27 1980-12-02 Miklos Bodanszky Polypeptides and methods of preparation
GB8427651D0 (en) * 1984-11-01 1984-12-05 Beecham Group Plc Compounds
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
US5972883A (en) * 1993-03-16 1999-10-26 Yeda Research And Development Co. Ltd. Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
US5808037A (en) * 1995-09-15 1998-09-15 Ramareddy Venkata Guntaka Oligomers which inhibit expression of collagen genes
US20020115609A1 (en) * 1997-07-14 2002-08-22 Hayat Onyuksel Materials and methods for making improved micelle compositions
US5892162A (en) * 1997-11-18 1999-04-06 Southwest Research Institute Apparatus and method for inspection of pipes and tubes using guided wave probe
US6635273B1 (en) * 1999-10-29 2003-10-21 Trustees Of Boston University Methods of treating vascular diseases characterized by nitric oxide insufficiency
CA2395165C (en) * 2000-10-20 2012-05-22 Mario Ehlers Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
WO2002043746A2 (en) * 2000-11-28 2002-06-06 Mondobiotech Sa Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
US6911430B2 (en) * 2003-10-01 2005-06-28 Vipogen, Llc Compositions and methods for treating ileus
CA2567635A1 (en) * 2004-05-21 2005-12-01 Eli Lilly And Company Selective vpac2 receptor peptide agonists
EP1755564B1 (en) * 2004-05-21 2013-10-16 Accu-Break Technologies, Inc. Immediate release pharmaceutical tablets with height greater than width
EP1768689B1 (en) * 2004-06-11 2014-08-20 Vectus Biosystems Limited Compositions and methods for treatment of cardiovascular disease
AU2006322656B2 (en) * 2005-12-09 2012-03-08 Vectus Biosystems Limited VIP fragments and methods of use
WO2008073146A2 (en) * 2006-07-06 2008-06-19 University Of Wyoming Method and apparatus for pyrolysis-induced cleavage in peptides and proteins
WO2010042997A1 (en) * 2008-10-17 2010-04-22 Vectus Biosystems Pty Limited Compositions and methods for treatment of kidney disorders
BRPI1006748A2 (pt) * 2009-04-02 2018-03-06 Vectus Biosystems Pty Ltd método de tratamento profilático ou terapêutico de fibrose aórtica em um indivíduo, peptídeo intestinal vasoativo (vip), uso do peptídeo intestinal vasoativo (vip), método para reduzir a formação de colágeno ou para realçar a degradação de colágeno na orta de um indivíduo, e, composição para o tratamento profilático ou terapêutico de fibrose aórtica

Also Published As

Publication number Publication date
RU2008127877A (ru) 2010-01-20
JP2009518316A (ja) 2009-05-07
AR109274A2 (es) 2018-11-14
NZ604248A (en) 2014-07-25
US20160222078A1 (en) 2016-08-04
EP1976548A1 (en) 2008-10-08
EP2783697A3 (en) 2015-01-07
CN101325964B (zh) 2013-09-18
BRPI0620566A2 (pt) 2011-11-16
DK2783697T3 (en) 2017-04-10
IL224609A (en) 2014-05-28
RU2466738C2 (ru) 2012-11-20
IL192046A (en) 2014-03-31
US9732136B2 (en) 2017-08-15
WO2007065226A1 (en) 2007-06-14
DK1976548T3 (da) 2014-10-06
ES2523858T3 (es) 2014-12-02
KR20080075551A (ko) 2008-08-18
NZ597677A (en) 2013-05-31
EP2783697A2 (en) 2014-10-01
US20090005315A1 (en) 2009-01-01
EP1976548B1 (en) 2014-07-02
NZ623674A (en) 2014-07-25
AR058308A1 (es) 2008-01-30
US8916523B2 (en) 2014-12-23
IL230534A (en) 2014-12-31
CA2632581A1 (en) 2007-06-14
EP2783697B1 (en) 2017-01-11
PT1976548E (pt) 2014-10-13
AU2006322656B2 (en) 2012-03-08
JP5730820B2 (ja) 2015-06-10
CN101325964A (zh) 2008-12-17
CA2952475C (en) 2022-08-09
EP1976548A4 (en) 2012-04-18
ES2621864T3 (es) 2017-07-05
US20130244934A1 (en) 2013-09-19
TWI402273B (zh) 2013-07-21
TW200730538A (en) 2007-08-16
BRPI0620566B8 (pt) 2021-05-25
JP2014097994A (ja) 2014-05-29
CA2632581C (en) 2017-02-07
CN103450345A (zh) 2013-12-18
HK1122746A1 (en) 2009-05-29
US9340583B2 (en) 2016-05-17
JP2012229222A (ja) 2012-11-22
BRPI0620566B1 (pt) 2018-07-24
JP5449778B2 (ja) 2014-03-19
CA2952475A1 (en) 2007-06-14
KR101404561B1 (ko) 2014-06-11
NZ569401A (en) 2012-03-30
ZA200805837B (en) 2009-05-27
US20150065424A1 (en) 2015-03-05
JP5847793B2 (ja) 2016-01-27
KR20140041943A (ko) 2014-04-04
CN103450345B (zh) 2016-04-20
US8470778B2 (en) 2013-06-25
IL192046A0 (en) 2008-12-29
AU2006322656A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
PL1951838T3 (pl) Kompozycje zawierające fluoroolefiny i ich zastosowania
PL1883665T3 (pl) Kompozycje polilaktydowe i ich zastosowania
GB0522287D0 (en) Method and compositions
IL187617A0 (en) Lkktet and/or lkktnt peptide compositions and methods
ZA200704295B (en) Arthrospira-based compositions and uses thereof
IL192046A0 (en) Vip fragments and methods of use
IL184834A0 (en) Compositions and methods for the manufacture thereof
GB0525314D0 (en) Method and composition
GB0506044D0 (en) Composition
GB0508250D0 (en) Composition
GB0507167D0 (en) Composition
EP1847249A4 (en) hair dye
ZA200802969B (en) Composition and method
GB0617171D0 (en) Novel compositions and methods
GB0524927D0 (en) Compositions and method
ZA200805079B (en) Immunostimulatory compositions and methods
EP1947129A4 (en) PHOTORADIC AND PHOTOCYSTIC CURING COMPOSITION
GB0511235D0 (en) Compositions and method
GB0522655D0 (en) Composition and method
GB0501348D0 (en) Compositions and methods
ZA200604686B (en) Mortar compositions, methods and applications therefor
GB0502341D0 (en) Composition
GB0513641D0 (en) Anti-egeing composition
GB0504185D0 (en) Improved glazing composition and uses thereof
GB0525968D0 (en) Compositions and methods